Chronic Myeloid Leukemia Medical Services in China

Chronic Myeloid Leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the uncontrolled proliferation of myeloid lineage cells—particularly granulocytes—in the bone marrow and peripheral blood. It is defined molecularly by the presence of the Philadelphia chromosome (Ph+), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11.2)], which generates the BCR-ABL1 fusion oncogene. This chimeric gene encodes a constitutively active tyrosine kinase that drives aberrant cell survival, proliferation, and impaired apoptosis—fundamental hallmarks of CML pathogenesis. CML typically progresses through three clinical phases: chronic phase (CP), accelerated phase (AP), and blast phase (BP); most patients are diagnosed in CP, where symptoms are often subtle or absent. Epidemiologically, CML accounts for approximately 15% of adult leukemias in Western populations, with an annual incidence of 1–2 cases per 100,000 individuals. It predominantly affects adults, with a median age at diagnosis of 64 years; pediatric cases are rare (<5% of all CML). No strong environmental or lifestyle risk factors have been consistently identified—unlike many cancers, CML is not linked to smoking, diet, or occupational exposures. Ionizing radiation remains the only well-established risk factor, notably observed in atomic bomb survivors. The disease’s chronic nature and lifelong treatment requirements significantly impact quality of life: patients may experience persistent fatigue, early satiety (due to splenomegaly), night sweats, weight loss, and anxiety related to treatment adherence, monitoring burden (e.g., monthly PCR testing), and fear of progression or resistance. While modern tyrosine kinase inhibitors (TKIs)—such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib—have transformed CML into a manageable chronic condition with near-normal life expectancy for most CP patients, long-term toxicities (e.g., cardiovascular events, pleural effusions, metabolic disturbances) and financial strain from prolonged therapy remain critical concerns. Psychosocial support, patient education, and integrated care models are increasingly emphasized to preserve functional status and emotional well-being throughout decades of treatment.

Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative neoplasm originating from a pluripotent hematopoietic stem cell. The defining molecular event in virtually all cases (>95%) is the Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22—t(9;22)(q34;q11.2). This translocation fuses the breakpoint cluster region (BCR) gene on chromosome 22 with the Abelson murine leukemia viral oncogene homolog 1 (ABL1) gene on chromosome 9, generating the oncogenic BCR-ABL1 fusion gene. The chimeric BCR-ABL1 protein exhibits constitutively active tyrosine kinase activity, leading to dysregulated proliferation, impaired apoptosis, altered adhesion, and genomic instability in myeloid progenitor cells. While the t(9;22) is the proximal cause, it is not sufficient alone to induce full-blown CML; secondary genetic and epigenetic alterations—such as mutations in ASXL1, RUNX1, IKZF1, or TP53, or chromosomal abnormalities like trisomy 8 or isochromosome 17q—are often required for disease progression from chronic phase to accelerated or blast phase.

No definitive exogenous trigger initiates the t(9;22) translocation; it is considered a stochastic, acquired somatic event occurring spontaneously in a single hematopoietic stem cell. However, certain environmental exposures are associated with increased risk of developing CML, albeit with modest effect sizes and inconsistent epidemiological evidence. Ionizing radiation is the most robustly established environmental risk factor: survivors of atomic bomb explosions and patients exposed to high-dose therapeutic radiation (e.g., for ankylosing spondylitis or prior malignancies) demonstrate elevated CML incidence. In contrast, diagnostic radiography and low-dose occupational exposure show no consistent association. Benzene exposure—particularly chronic, high-level occupational exposure—is linked to increased risk of acute myeloid leukemia but has only weak or inconclusive associations with CML. Similarly, tobacco smoking, pesticides, and solvents have been investigated, yet large cohort and case-control studies fail to confirm reproducible, independent associations with CML incidence.

Genetic predisposition plays a minimal role in typical CML. Unlike hereditary cancer syndromes (e.g., Li-Fraumeni or Fanconi anemia), CML is not inherited, and germline variants conferring substantial susceptibility have not been identified. Genome-wide association studies (GWAS) have reported modest associations with single-nucleotide polymorphisms (SNPs) near genes involved in immune regulation (e.g., CDKN2B-AS1, HLA-DQB1), DNA repair (e.g., RAD51B), and telomere maintenance (e.g., TERT), but these confer very small increases in relative risk (odds ratios <1.3) and lack clinical utility for risk prediction. Familial clustering of CML is exceedingly rare and likely attributable to shared environmental exposures or chance rather than autosomal dominant inheritance.

Established demographic and clinical risk factors include age and sex. CML incidence rises steadily with age, with a median diagnosis age of 64 years; it is uncommon in children and adolescents (<5% of cases). Males are affected approximately 1.3–1.5 times more frequently than females, though the biological basis remains unclear—hypotheses include hormonal modulation of hematopoietic stem cell kinetics or differential exposure patterns. Socioeconomic status and ethnicity show minor variations in incidence rates across populations, but these likely reflect disparities in healthcare access and diagnostic ascertainment rather than intrinsic biological risk. Notably, prior cytotoxic chemotherapy (e.g., alkylating agents or topoisomerase II inhibitors) is associated with therapy-related myeloid neoplasms but does not specifically increase CML risk; such cases remain overwhelmingly Ph-negative.

Importantly, many commonly presumed risk factors—including diet, alcohol consumption, viral infections (e.g., EBV, HIV, HTLV-1), autoimmune disorders, and prior solid tumors—lack credible epidemiological or mechanistic support as contributors to CML pathogenesis. The disease is not contagious, nor is it preventable through lifestyle modification. Current understanding emphasizes that CML arises from a random, acquired chromosomal aberration in a stem cell, with age being the strongest non-modifiable risk factor and ionizing radiation the only well-substantiated environmental exposure. Ongoing research focuses on elucidating the microenvironmental and inflammatory cues that may foster the survival and expansion of the BCR-ABL1–positive clone, particularly during the preclinical phase.

Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative neoplasm arising from a pluripotent hematopoietic stem cell, characterized by the Philadelphia chromosome (t(9;22)(q34;q11.2)) and its resultant BCR-ABL1 fusion oncogene. CML typically follows a triphasic clinical course—chronic phase (CP), accelerated phase (AP), and blast phase (BP)—with symptomatology evolving in parallel with disease progression. Early symptoms are often subtle, nonspecific, and frequently absent; approximately 30–50% of patients are asymptomatic at diagnosis and identified incidentally during routine blood testing.

Early symptoms—when present—reflect mild myeloproliferation and early bone marrow compromise. Patients may report persistent fatigue, low-grade malaise, or unexplained weight loss (>10% body weight over six months). Mild night sweats and low-grade fever (<38.3°C) occur in ~15–20% of chronic-phase cases and are attributed to cytokine dysregulation rather than infection. Early splenomegaly may cause vague left upper quadrant discomfort or early satiety due to gastric compression; however, physical examination may reveal only a minimally enlarged, non-tender spleen. Some patients note easy bruising or prolonged bleeding after minor trauma, reflecting platelet dysfunction despite normal or elevated platelet counts—a phenomenon linked to qualitative defects in platelet granule release and adhesion.

Typical symptoms in established chronic-phase CML reflect progressive expansion of malignant myeloid precursors and organ infiltration. Splenomegaly becomes clinically apparent in >70% of patients, often extending >5 cm below the left costal margin; it may cause left-sided abdominal pain, early satiety, postprandial bloating, and occasionally referred left shoulder pain (Kehr sign). Hepatomegaly occurs less frequently (~20–30%) and is usually mild. Anemia-related manifestations—including pallor, exertional dyspnea, palpitations, and reduced exercise tolerance—emerge as erythropoiesis is suppressed by marrow crowding. Thrombocytosis (>450 × 10⁹/L) is common (present in ~30–50% of CP cases) but rarely causes thrombotic events unless extreme (>1000 × 10⁹/L) or accompanied by JAK2 V617F co-mutation. Conversely, thrombocytopenia may develop later in CP or herald transition to AP/BP. Leukocytosis is nearly universal (median WBC 100–300 × 10⁹/L), yet patients seldom experience leukostasis-related symptoms (e.g., headache, visual disturbance, priapism) unless WBC exceeds 500 × 10⁹/L or blast count rises significantly.

Accompanying symptoms include gouty arthritis or nephrolithiasis due to tumor lysis-induced hyperuricemia—even in untreated CP—particularly following rapid cell turnover or initiation of cytoreductive therapy. Bone pain (especially sternal or vertebral) may occur secondary to marrow expansion or focal osteosclerosis. Recurrent or atypical infections are uncommon in CP but increase in frequency during AP/BP due to functional neutrophil defects and progressive immunosuppression. Some patients report pruritus, especially after warm showers (aquagenic pruritus), possibly related to mast cell activation and histamine release within the expanded myeloid compartment.

Complications arise predominantly during disease progression. Accelerated phase is defined by ≥1 of the following: basophils ≥20% in peripheral blood or bone marrow; blasts 10–19% in blood or marrow; new cytogenetic abnormalities (e.g., +8, i(17q), +19, +Ph); persistent thrombocytopenia (<100 × 10⁹/L) unrelated to therapy; or thrombocytosis (>1000 × 10⁹/L) unresponsive to therapy. Clinically, AP manifests as worsening constitutional symptoms (fever, night sweats, weight loss), increasing splenomegaly, progressive cytopenias, or recurrent infections. Blast phase (≥20% blasts in blood or marrow, or extramedullary blast proliferation) mimics acute leukemia: patients develop profound cytopenias, life-threatening infections, disseminated intravascular coagulation (DIC), leukostasis (retinal hemorrhages, pulmonary infiltrates, stroke), or chloroma (granulocytic sarcoma) presenting as soft-tissue masses (e.g., orbital, paraspinal, lymph node). Additional complications include portal or splenic vein thrombosis (due to hyperviscosity and endothelial activation), autoimmune phenomena (e.g., immune thrombocytopenia, autoimmune hemolytic anemia), and therapy-related myelodysplasia following prolonged tyrosine kinase inhibitor (TKI) exposure.

Diagnosis relies on integrated morphologic, cytogenetic, molecular, and flow cytometric evaluation. Complete blood count (CBC) typically reveals leukocytosis with a full spectrum of myeloid precursors (myelocytes, metamyelocytes, bands), basophilia (>2%), eosinophilia, and variable anemia/thrombocytosis. Peripheral blood smear shows no dysplasia but may demonstrate teardrop cells or nucleated RBCs if extramedullary hematopoiesis is prominent. Bone marrow aspiration and biopsy demonstrate hypercellularity (>90% cellularity), granulocytic hyperplasia, increased myeloid:erythroid ratio (>10:1), and preserved megakaryocyte morphology (unlike essential thrombocythemia or primary myelofibrosis). Cytogenetics remains the gold standard: detection of t(9;22) in ≥20 metaphases confirms diagnosis. Fluorescence in situ hybridization (FISH) for BCR-ABL1 detects cryptic rearrangements missed by karyotyping. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) measures BCR-ABL1 transcript levels (expressed as % BCR-ABL1/ABL1 on International Scale) for diagnosis, risk stratification, and response monitoring. Additional testing includes JAK2 V617F, CALR, and MPL mutation analysis to exclude other myeloproliferative neoplasms, and serum uric acid, lactate dehydrogenase (LDH), and vitamin B12 (often markedly elevated due to granulocyte storage).

Differential diagnosis includes other BCR-ABL1-negative myeloproliferative neoplasms: essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). ET presents with isolated thrombocytosis (>450 × 10⁹/L), normal WBC, and absence of significant splenomegaly or basophilia; JAK2/CALR/MPL mutations are detectable. PV features erythrocytosis (hematocrit >49% men, >48% women), often with associated leukocytosis and thrombocytosis, and JAK2 V617F positivity in >95%. PMF demonstrates marked splenomegaly, tear-drop poikilocytes, bone marrow fibrosis, and abnormal megakaryocyte clustering; BCR-ABL1 is absent. Chronic neutrophilic leukemia (CNL) shows sustained mature neutrophilia (>25 × 10⁹/L), absence of dysplasia, and CSF3R T618I mutation; BCR-ABL1 negative. Juvenile myelomonocytic leukemia (JMML) occurs almost exclusively in children and features monocytosis, hypersensitivity to GM-CSF, and RAS pathway mutations. Reactive leukemoid reactions (e.g., severe infection, malignancy, inflammatory disorders) may mimic CML but lack BCR-ABL1, show appropriate neutrophil maturation without basophilia, and resolve with treatment of the underlying condition. Finally, Ph-like ALL must be distinguished in younger adults presenting with high WBC and blasts; it lacks BCR-ABL1 but exhibits alternative kinase-activating lesions (e.g., CRLF2 rearrangements, ABL-class fusions) and requires RNA sequencing for identification.

Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative neoplasm driven by the BCR-ABL1 fusion oncogene, resulting from the reciprocal translocation t(9;22)(q34;q11.2)—the Philadelphia chromosome. Diagnosis requires confirmation of BCR-ABL1 via quantitative reverse transcription polymerase chain reaction (qRT-PCR), fluorescence in situ hybridization (FISH), or cytogenetic analysis. Treatment strategy is risk-stratified and response-guided, with the primary goal of achieving deep molecular responses to prevent progression to accelerated or blast phase disease.

Conservative management plays a supportive role rather than serving as definitive therapy. It includes regular hematologic monitoring (complete blood count every 2–4 weeks during initial therapy), assessment of spleen size, and evaluation for symptoms such as fatigue, night sweats, weight loss, or early satiety. Patients with low-risk CML (Sokal or EUTOS score low) and minimal symptom burden may undergo observation only during the very early chronic phase—though this is exceedingly rare in contemporary practice due to the high efficacy and tolerability of tyrosine kinase inhibitors (TKIs). Conservative measures also encompass transfusion support for symptomatic anemia or thrombocytopenia, hydroxyurea for rapid leukocyte reduction prior to TKI initiation, and allopurinol or rasburicase for tumor lysis prophylaxis in high-burden cases. Infection surveillance and vaccination (e.g., pneumococcal, influenza, and SARS-CoV-2 vaccines) are integral, particularly given the immunomodulatory effects of long-term TKI therapy.

Medication remains the cornerstone of CML treatment. First-line therapy consists of second-generation TKIs—nilotinib, dasatinib, or bosutinib—or imatinib, though the latter is now less favored due to inferior depth and speed of molecular response. Second-generation agents achieve major molecular response (MMR; BCR-ABL1 ≤0.1% IS) in >70% of patients at 12 months versus ~60% with imatinib. Third-generation TKI ponatinib is reserved for patients with T315I mutation or those failing ≥2 prior TKIs. Asciminib, a first-in-class STAMP inhibitor (specifically targeting the ABL myristoyl pocket), has demonstrated robust efficacy and improved safety in refractory/intolerant CML, including T315I-mutated disease. Treatment response is monitored rigorously: cytogenetics at 3 and 6 months; qRT-PCR every 3 months for the first 2 years, then every 3–6 months upon sustained MMR. Failure or suboptimal response triggers mutation analysis (ABL1 kinase domain sequencing) and therapeutic adjustment. Treatment-free remission (TFR) is a realistic goal for eligible patients—those maintaining deep molecular response (MR4.5; BCR-ABL1 ≤0.0032% IS) for ≥2 years—under close molecular surveillance after TKI discontinuation.

Surgical treatment has no curative role in CML. Splenectomy may be considered in rare instances of massive, symptomatic splenomegaly unresponsive to medical therapy or causing mechanical complications (e.g., gastric compression, infarction, or hypersplenism with severe cytopenias). However, it carries significant morbidity—including infection risk (especially encapsulated organisms), thromboembolism, and potential acceleration of extramedullary disease—and is largely obsolete in the TKI era. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative modality but is restricted to patients with TKI resistance, intolerance, disease progression to accelerated/blast phase, or specific high-risk features (e.g., additional chromosomal abnormalities in Ph+ cells). Due to substantial transplant-related mortality (15–25%) and morbidity (graft-versus-host disease, infections), allo-HSCT is not recommended in chronic-phase CML with adequate TKI response. Its use has declined markedly since the advent of potent TKIs, now representing <5% of all CML treatments in high-resource settings.

China offers distinct advantages in CML care. First, national health insurance coverage includes multiple TKIs—including imatinib, nilotinib, dasatinib, and increasingly asciminib—with significantly reduced out-of-pocket costs following inclusion in the National Reimbursement Drug List (NRDL). Second, China’s centralized, high-volume leukemia centers (e.g., Peking University People’s Hospital, Ruijin Hospital, Sun Yat-sen University Cancer Center) maintain standardized, protocol-driven monitoring aligned with ELN and NCCN guidelines, supported by robust real-time qRT-PCR infrastructure and centralized reference laboratories. Third, China leads globally in TKI pharmacovigilance and real-world evidence generation through large-scale registries like the Chinese CML Registry, enabling rapid identification of regional toxicity patterns (e.g., higher incidence of pleural effusion with dasatinib in East Asian populations) and informing personalized dosing strategies. Fourth, domestic innovation has accelerated: Hefei-based biotech firms have developed novel TKIs (e.g., olverembatinib) approved in China for T315I-mutated CML, offering alternatives where ponatinib access is limited. Finally, integrated traditional Chinese medicine (TCM) adjuncts—such as Jiedu Xiaozheng decoction—are used under rigorous clinical protocols to mitigate TKI-induced adverse effects (e.g., hepatotoxicity, myelosuppression), with emerging randomized data supporting improved quality-of-life metrics without compromising molecular response.

Recovery and long-term management emphasize adherence, surveillance, and lifestyle optimization. Patients must maintain strict TKI adherence (>90% dose intensity); missed doses correlate strongly with resistance development. Annual cardiovascular risk assessment (lipid panel, echocardiogram if on dasatinib, ECG for QTc prolongation with nilotinib) is mandatory. Bone mineral density screening is recommended after 5 years of TKI therapy due to increased osteoporosis risk. Psychosocial support—including counseling and peer-led survivorship programs—is vital, as anxiety about relapse and financial toxicity persist despite treatment advances. Nutrition should prioritize anti-inflammatory foods (leafy greens, fatty fish, berries) and avoid grapefruit (CYP3A4 inhibition) with most TKIs. Moderate aerobic exercise (150 min/week) improves fatigue and immune resilience. Pregnancy planning requires multidisciplinary coordination: TKI cessation or switch to safer agents (e.g., imatinib) preconception, with close fetal monitoring. Finally, patients should receive annual influenza and pneumococcal vaccines, avoid live vaccines during active TKI therapy, and seek prompt evaluation for persistent fever, bruising, or lymphadenopathy—potential signs of progression. With modern TKI regimens, median overall survival exceeds 20 years, and many patients attain near-normal life expectancy when managed in specialized hematology centers.